KRAS mutation analysis in ovarian samples using a high sensitivity biochip assay.
about
Histone deacetylases as new therapy targets for platinum-resistant epithelial ovarian cancerThe Association between Endometriomas and Ovarian Cancer: Preventive Effect of Inhibiting Ovulation and Menstruation during Reproductive LifeEndometriosis and ovarian cancer: links, risks, and challenges facedThe molecular background of mucinous carcinoma beyond MUC2The B-Raf status of tumor cells may be a significant determinant of both antitumor and anti-angiogenic effects of pazopanib in xenograft tumor modelsThe origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theoryAnalysis and comparison of somatic mutations in paired primary and recurrent epithelial ovarian cancer samples.An integrative approach to identifying cancer chemoresistance-associated pathwaysEndometriosis and ovarian cancer: a review of clinical, pathologic, and molecular aspects.Discovery of prognostic factors for diagnosis and treatment of epithelial-derived ovarian cancer from laying hens.REDD1 and p-AKT over-expression may predict poor prognosis in ovarian cancerMultiple genetic alterations within the PI3K pathway are responsible for AKT activation in patients with ovarian carcinomaCancer-associated fibroblasts and their putative role in potentiating the initiation and development of epithelial ovarian cancer.Overexpression of the β subunit of human chorionic gonadotropin promotes the transformation of human ovarian epithelial cells and ovarian tumorigenesis.Biochip-based detection of KRAS mutation in non-small cell lung cancer.Inhibition of epithelial ovarian cancer by Minnelide, a water-soluble pro-drug.Identification of multiple pathways involved in the malignant transformation of endometriosis (Review)Mutant p53 Promotes Epithelial Ovarian Cancer by Regulating Tumor Differentiation, Metastasis, and Responsiveness to Steroid Hormones.Clinicopathological correlates and prognostic significance of KRAS mutation status in a pooled prospective cohort of epithelial ovarian cancer.Pathway modulations and epigenetic alterations in ovarian tumorbiogenesis.Targeting the epidermal growth factor receptor in epithelial ovarian cancer: current knowledge and future challenges.Ovarian borderline tumors in the 2014 WHO classification: evolving concepts and diagnostic criteria.Ovarian cancer in endometriosis: clinical and molecular aspects.Multipoint Kras oncogene mutations potentially indicate mucinous carcinoma on the entire spectrum of mucinous ovarian neoplasms.New and potential clinical applications of KRAS as a cancer biomarker.Oncogenes associated with drug resistance in ovarian cancer.KRAS mutation detection in paired frozen and Formalin-Fixed Paraffin-Embedded (FFPE) colorectal cancer tissuesA case of synchronous pancreatic ductal adenocarcinoma and ovarian mucinous cystic neoplasm: use of kras mutation molecular phenotyping to demonstrate independent primary origin.The status of Her2 amplification and Kras mutations in mucinous ovarian carcinoma.Mutational status of KRAS, NRAS, and BRAF in primary clear cell ovarian carcinoma.Distinct methylation profile of mucinous ovarian carcinoma reveals susceptibility to proteasome inhibitors.Distinct molecular profiles in Lynch syndrome-associated and sporadic ovarian carcinomas.HPIP promotes epithelial-mesenchymal transition and cisplatin resistance in ovarian cancer cells through PI3K/AKT pathway activation.
P2860
Q26777453-27E0073A-24F3-43CF-94A4-F9F2F0114052Q26785614-53570C25-173D-4183-B771-2E1E11819FA1Q27003273-2B5B0BE1-C487-40B5-A6EF-2E0E5CA68C08Q28083904-5D2B3889-333F-46C8-99BB-38D1535504BDQ28744228-79635643-FA53-4AB0-8AD6-34357F5061B0Q33739695-25D39697-6B83-4685-A5E4-795729A3B36DQ33768759-7E25A23F-6A3F-454A-A882-AF11AB829CBDQ33853380-63A69C54-F357-4A50-B409-2178B62A2E47Q34033619-B8D49055-0C58-417C-A827-45CD484FED50Q34305434-0C88AF92-1C00-4190-AA3F-9A6ACA7765D8Q34371477-5EAFB65F-CF12-482B-802F-7AE9764C6EF6Q34586019-A180C437-E38D-4950-B5DA-5C6A5D8D160AQ34887528-D45BB518-1F12-4652-90DC-21C1052B0655Q35168182-432C70F4-0994-46D3-9F00-D5A8BA0F4805Q35669440-45FAEB4E-9AF0-4953-B6FC-65BCEA32D85CQ36092073-7F5F6DBE-64BB-4A1C-898B-7C68ACCDA058Q36099250-FD815F42-AE88-450A-BE57-5062ABBC904FQ36917897-82D176A9-3991-40F8-9C87-89522F08B7F5Q37042308-04051256-5ED3-4D63-9509-DA3F61F9F0F7Q37420213-37CE946B-F634-4A9B-96CE-03BC64F6030CQ37485865-2A49F373-0645-4D90-82F1-E4CEBD95E3C4Q37632101-617BE80F-2F34-4FB9-A300-B413025AF419Q37645709-F9F306D8-98A1-4964-8EC9-6419885420A7Q37696086-CE2E0D45-34A5-4C48-A2DA-705E6A3FFE74Q38089885-68B2E120-DA5F-4459-80EF-BE83B0BE1A86Q38226577-E0E17226-C084-4A1D-AA83-2E0AE0C9BAF2Q38409695-7C40142E-481B-4CA6-812E-6EA7F2A7B0B9Q42186610-975F5EB3-435A-4287-A426-33E1EB1C2761Q42339944-44CF473C-CEA3-4B2F-BAAA-7DB6BBF350D3Q46879650-A38BC00E-B193-4CC9-8F01-D947C6867E4CQ49937490-5E862916-7B74-46AB-A033-EF62ED69C847Q50742113-E4F70624-8D93-48E9-8E86-25F16B3BFAC2Q52808198-D95212CE-660C-41E5-AE5D-A08F20005FC2
P2860
KRAS mutation analysis in ovarian samples using a high sensitivity biochip assay.
description
2009 nî lūn-bûn
@nan
2009 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
KRAS mutation analysis in ovarian samples using a high sensitivity biochip assay.
@ast
KRAS mutation analysis in ovarian samples using a high sensitivity biochip assay.
@en
type
label
KRAS mutation analysis in ovarian samples using a high sensitivity biochip assay.
@ast
KRAS mutation analysis in ovarian samples using a high sensitivity biochip assay.
@en
prefLabel
KRAS mutation analysis in ovarian samples using a high sensitivity biochip assay.
@ast
KRAS mutation analysis in ovarian samples using a high sensitivity biochip assay.
@en
P2093
P2860
P356
P1433
P1476
KRAS mutation analysis in ovarian samples using a high sensitivity biochip assay.
@en
P2093
Alexander Mustea
Alexander Reinthaller
Gernot Kriegshäuser
Reinhard Horvat
Veronika Auner
P2860
P2888
P356
10.1186/1471-2407-9-111
P407
P577
2009-04-09T00:00:00Z
P5875
P6179
1002772136